{"denoms":[{"counts":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"89"}],"units":"Participants"}],"groups":[{"description":"Patients receive low-dose melphalan 20 mg/m\\^2 IV over 15-30 minutes on day 1 or 0.12 mg/kg tablet orally once daily on days 1-7 and dexamethasone 40 mg orally on days 1-4 and 22-25. Treatment repeats every 6 weeks for 10 courses. (Study treatment beyond one year is not allowed.)","id":"BG000","title":"Low-Dose Melphalan"},{"description":"Patients receive filgrastim (G-CSF) 10 mg/kg/day on days -7 to -3 and undergo autologous hematopoietic stem cell (HSC) collection. Patients receive high-dose melphalan 140 mg/m\\^2 IV for low risk or 200 mg/m\\^2 IV for high risk patients over 1 hour on days -2 and -1 and undergo autologous HSC transplantation on day 0.","id":"BG001","title":"High-Dose Melphalan + Autologous HSC"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"48","upperLimit":"74","value":"62"},{"groupId":"BG001","lowerLimit":"44","upperLimit":"73","value":"57"},{"groupId":"BG002","lowerLimit":"44","upperLimit":"74","value":"59"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"33"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"56"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"51"},{"groupId":"BG002","value":"83"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"89"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"75"}]}],"title":"0-1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"14"}]}],"title":"2"}],"description":"Classifies patients according to their functional impairment. 0: Fully active, able to carry on all pre-disease performance without restriction; 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours","paramType":"NUMBER","title":"ECOG Performance Score","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"58"}]}],"title":"Low"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"31"}]}],"title":"High"}],"description":"Low Risk (requires all of the following): 1 or 2 organs involved, Cardiac EF \\>= 50%, Age \\<= 65 years, NYHA class 1 or 2, Alkaline phosphatase \\<= 4 x institutional ULN, cardiac involvement fully compensated or asymptomatic, serum creatinine \\<= 2.0 mg/dL\n\nHigh Risk (any one of the following): \\>2 organs involved, Cardiac EF \\<50%, Age \\> 65 years, NYHA class 3, Alkaline phosphatase 4-6 x institutional ULN, symptomatic cardiac involvement, serum creatinine 2.1-3.0 mg/dL","paramType":"NUMBER","title":"Risk Group","unitOfMeasure":"participants"}]}